MARKET

RVMD

RVMD

Revolution Medicines, Inc.
NASDAQ
101.83
-0.91
-0.89%
After Hours: 100.50 -1.33 -1.31% 19:59 02/20 EST
OPEN
102.72
PREV CLOSE
102.74
HIGH
102.82
LOW
100.20
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
124.49
52 WEEK LOW
29.17
MARKET CAP
19.69B
P/E (TTM)
-19.6663
1D
5D
1M
3M
1Y
5Y
1D
Is Revolution Medicines (RVMD) Pricing In Pipeline Progress After A 135.7% One Year Surge?
Simply Wall St · 3d ago
Revolution Medicines Inc. updates financial calendar
Reuters · 4d ago
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing
The Motley Fool · 4d ago
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Barchart · 4d ago
A Look At Revolution Medicines (RVMD) Valuation After Strong One Year Shareholder Returns
Simply Wall St · 4d ago
Revolution Medicines placed on ‘Positive Catalyst Watch’ at JPMorgan
TipRanks · 5d ago
Weekly Report: what happened at RVMD last week (0209-0213)?
Weekly Report · 6d ago
Royalty Pharma Q4 adjusted EBITDA beats analyst expectations
Reuters · 02/11 12:11
More
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Webull offers Revolution Medicines Inc stock information, including NASDAQ: RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVMD stock methods without spending real money on the virtual paper trading platform.